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Stroke outcome considerably varies between stroke patients and often cannot be predicted. Now, Gendrun and
colleagues investigated the suitability of blood neurofilament light chain proteins (NFL) as a biomarker of neuronal
damage. High NFL levels correlated with brain injury, functional outcome and mortality following all major types of
stroke. These data raise hope to revolutionize future prognosis and management of stroke patients.
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Main text
Stroke is a leading cause of disability and death world-
wide. Over 13.7 million strokes occur each year, and
one in four people over 25 years will experience a stroke
in their lifetime.1 The presence of life-saving medicines
allows timely intervention and significantly decreased
mortality following stroke.2 On the other hand, overall
stroke outcome can vary considerably between individ-
ual patients from asymptomatic and non-disabling to
permanent-disability or death. Current clinical meas-
ures include the assessment through an experienced
stroke clinician and are supplemented with advanced
neuroimaging such as magnetic resonance imaging
(MRI) and computed tomography (CT) to determine
the injured stroke area and brain damage. However,
this advanced healthcare infrastructure is inaccessible
for many patients especially in low and middle-income
countries and/or in rural regions. Although clinical
assessments provide important insight into overall
stroke severity, they are often crude and have only
moderate correlation with actual brain tissue damage
and long-term outcome.3 Thus, potential easily avail-
able blood biomarkers (see here for an overview of
biomarkers 4) are urgently needed to guide individual-
ized stroke patient treatment. Now, research by
Gendron and colleagues 5 identified elevated levels of
Neurofilament light chain protein (NFL) in multiple
cohorts of stroke patients and raise hope towards a
universal prognostic blood biomarker for brain injury.
While blood biomarkers such as troponin have rev-
olutionized the prognosis and management of myocar-
dial infarction (MI), the development of blood
biomarkers for stroke faces difficulties. Strokes tend
to be a more heterogeneous condition than ischemic
heart diseases. Contrary to MI that is mainly caused
by atherosclerosis, causes of stroke also include small-
and large vessel disease, cardioembolism, dissections
and rare coagulopathies. Moreover, the blood-brain
barrier (BBB) considerably reduces the release of
brain tissue proteins into the blood circulation after
stroke, delaying the release of glial and neuronal pro-
teins. So far, a variety of individual prognostic blood
biomarkers have been identified that indicate neuronal
damage, inflammation or BBB disruption. Also panels
of biomarkers have been suggested to predict stroke
outcome. However, most of the studies on blood
markers reside still in an exploratory phase, and
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therefore used rather small cohorts and only few were
controlled for potential confounding factors.
Among others, NFLs have emerged as promising
prognostic biomarkers in stroke.6,7 Since NFL proteins
are major structural components of neurons, release of
NFL can be directly related to neuronal damage.
Previously, cerebrospinal fluid concentrations of NFL
have been associated with neuronal damage. However,
the more recent development of ultrasensitive assays
allowed also its quantification in the blood serum.6
As a consequence, the use of NFL as a marker of neu-
ronal damage became feasible in diseases where lumbar
puncture is not part of the clinical routine, such as
stroke. Given the heterogeneous pathology of stroke,
few initial studies concentrated on the correlation
between elevated NFL blood levels to outcomes of spe-
cific subtypes of stroke. Although most findings were
encouraging, interstudy discrepancies revealed the
need for more intensive investigations to verify NFL
as a universal blood biomarker for all major types
of stroke.
Here, Gendron and colleagues5 undertook a com-
prehensive study to investigate the suitability of blood
NFL as a uniform blood biomarker to predict the
degree of neuronal damage and mortality. The authors
generated a large multi-cohort dataset of stroke
patients categorized in acute cerebral infarction (ACI,
N¼ 227), subarachnoid hemorrhage (SAH, N¼ 58)
and intracerebral hemorrhage (ICH, N¼ 169). Their
findings indicate elevated levels of neurofilament light
(NFL) across all major types of stroke. Differences in
blood NFL between patients and control were most
evident at 9–20 days following stroke onset.
Interestingly, elevated NFL blood levels also correlated
with infarct volume, which was determined using CT-
based scores. To determine neurological, functional
and cognitive status of stroke patients at the time of
blood withdrawal, a panel of standard clinical meas-
ures were performed consisting of the National
Institutes of Health Stroke Scale (NIHSS), the modi-
fied Rankin Scale (mRS), and the Mini-Mental State
Examination (MMSE). In all stroke groups, higher
blood NFL levels were associated with a worse perfor-
mance for all the three tests. Strikingly, increased
plasma NFL serums collected within 20 days following
stroke were also able to reliably predict poor functional
recovery three and six months following stroke and
indicated an increased all-cause mortality within the
first three years (Figure 1).
These results encourage the use of NFL as a sub-
acute biomarker to forecast stroke outcome, complica-
tions and complement clinical routine in the near
future. The additional information might be used to
allocate healthcare resources and improve drug devel-
opment: (1) Patients with elevated NFL levels might be
referred to more intensive rehabilitation centers to
counteract an unfavorable clinical outcome; and (2)
efficacy of novel therapeutics might be assessed based
Figure 1. Time course of stroke and potential blood biomarkers. Current measures of stroke consist of clinical assessments and
neuronal imaging to confirm a stroke and initiate enzymatic thrombolysis (tPA) and/or mechanical thrombectomy (MT) treatment.
The therapeutic window of the treatments is 4–6.5 hours following stroke. Several days after stroke rehabilitative training begins and
can continue for months-years. Regular measures of motor and cognitive abilities are performed to determine long-term effects of
stroke e.g. NIHSS, MMSE, mRS. Types of Biomarker: To measure the risk to develop a disease (risk prediction); To confirm the
presence of a disease or identify subtypes (diagnosis); to identify probability to develop a clinical event in patients with a disease
(prognosis); to predict probability to develop any effect as consequence of clinical intervention (prediction); to monitor the status of a
disease and the response to an intervention (monitoring). tPA: tissue plasminogen activator; MT: mechanical thrombectomy, NIHSS:
National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; MMSE: Mini-Mental State Examination.
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on blood NFL levels. However, high blood NFL levels
are not specific for stroke and its release has been also
linked with other neurological conditions including
multiple sclerosis and traumatic brain injuries.8
Therefore, stroke patients and clinicians may further
benefit from recent advancements in the development
of risk prediction and diagnostic biomarkers. Increased
search for novel blood biomarker after stroke also
revealed other promising candidates e.g. hemojuvelin
to be an independent predictor of functional outcome
after stroke.9 Multilevel omics approaches have
revealed a panel of biomarkers to identify the likeli-
hood of developing a stroke or to diagnose and cate-
gorize the stroke type in the acute phase.10 Although it
is important to note that translating these exciting find-
ings into clinical routine would require further optimi-
zation and validation, a panel of diagnostic and
prognostic blood biomarkers have definitely great
potential to revolutionize stroke management and con-
tribute to individualized precision medicine for stroke
patients.
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